--- title: 'Clinical Daily Summary: What Happened on October 13, 2026' headline: Obuprazine meets its primary endpoint in a Phase 2b schizophrenia trial description: Syndax’s lung fibrosis drug failed a trial, while Elicera and Tridem shared updates on cell therapy and a Parkinson’s vaccine. url: https://thebench.bio/news/clinical/2026-10-13 topic: clinical date: '2026-10-13' covers: - '2026-10-13' date_published: '2026-10-13T12:01:58Z' date_modified: '2026-10-13T12:01:58Z' tags: - Clinical - Industry - Research sources: 6 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on October 13, 2026 **Obuprazine meets its primary endpoint in a Phase 2b schizophrenia trial** Syndax’s lung fibrosis drug failed a trial, while Elicera and Tridem shared updates on cell therapy and a Parkinson’s vaccine. ## Today in brief In a 363-person Phase 2b trial, all three obuprazine doses reduced schizophrenia symptom scores more than placebo after 42 days. [1] Syndax’s lung fibrosis drug failed a trial, and the company’s shares fell. [2] ## Obuprazine improved schizophrenia symptom scores versus placebo Tortugas Neuroscience and Hansoh Pharma said obuprazine met the primary endpoint in a randomized, double-blind Phase 2b study of adults with acute schizophrenia. [1] At day 42, the lowest-dose group’s average Positive and Negative Syndrome Scale (PANSS) score fell 28.6 points, compared with 11.9 points on placebo. [1] The placebo-adjusted differences were 16.7, 13.2 and 14.7 points for the low, middle and high doses, respectively. [1] At day 42, all three doses also improved positive and negative symptom scores and a cognitive measure versus placebo. [1] The companies said obuprazine’s results were numerically better than aripiprazole’s on several measures, including the primary endpoint. [1] Tortugas plans to file a US investigational new drug application and submit the full results to a peer-reviewed journal. [1] ## Also worth knowing - In the Phase 1 portion of the CARMA trial, eight of 12 patients treated with ELC-301 had complete metabolic responses, Elicera Therapeutics said. Six remained in response at their latest assessment, and no dose-limiting toxicities were reported across three dose groups. [3] - Tridem Bioscience enrolled the first patients in a Phase 1b trial assessing the safety and immune response to its Parkinson’s vaccine candidate TRB-001. The company expects top-line results in mid-2027. [4] - A secondary analysis found that patients’ own HIV antibodies and infused antibodies both helped delay viral rebound after antiretroviral therapy was paused. [5] - Ambry Genetics introduced GenomeNext, a whole-genome diagnostic test that uses a human pangenome reference, offers optional RNA analysis and includes ongoing case reanalysis. [6] ## The day in numbers - **8 of 12**: Patients treated with ELC-301 who had complete metabolic responses in Phase 1. [3] - **363**: Adults enrolled in the obuprazine Phase 2b schizophrenia trial. [1] ## Also published - [Females with autoimmune disease 'less likely to be believed'](), pharmaphorum - [Human–artificial intelligence collaboration for comanaging epilepsy in real time](), Nature Medicine - [Proteomic aging clocks go to trial](), Nature Biotechnology ## Sources 1. [Tortugas’ Phase IIb schizophrenia trial of obuprazine meets primary endpoint](), Clinical Trials Arena, 2026-10-13 2. [Syndax shares fall as lung fibrosis drug fails trial](), pharmaphorum, 2026-10-13 3. [Elicera’s CAR-T clears detectable lymphoma in eight patients](), European Biotechnology, 2026-10-13 4. [Tridem begins phase Ib trial of Parkinson’s disease vaccine](), Pharmafile, 2026-10-13 5. [Autologous and broadly neutralizing antibodies drive ART-free HIV control](), Nature Medicine, 2026-10-13 6. [Whole-Genome Diagnostics Evolve with RNA and Pangenome Integration](), Inside Precision Medicine, 2026-10-13 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: